Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109069

Decreased Glucagon Receptors in Diabetic Rat Hepatocytes: EVIDENCE FOR REGULATION OF GLUCAGON RECEPTORS BY HYPERGLUCAGONEMIA

Sam J. Bhathena, Nancy R. Voyles, Stewart Smith, and Lillian Recant

Diabetes Research Laboratory, Veterans Administration Hospital and Georgetown University, Washington, D. C. 20422

Find articles by Bhathena, S. in: PubMed | Google Scholar

Diabetes Research Laboratory, Veterans Administration Hospital and Georgetown University, Washington, D. C. 20422

Find articles by Voyles, N. in: PubMed | Google Scholar

Diabetes Research Laboratory, Veterans Administration Hospital and Georgetown University, Washington, D. C. 20422

Find articles by Smith, S. in: PubMed | Google Scholar

Diabetes Research Laboratory, Veterans Administration Hospital and Georgetown University, Washington, D. C. 20422

Find articles by Recant, L. in: PubMed | Google Scholar

Published June 1, 1978 - More info

Published in Volume 61, Issue 6 on June 1, 1978
J Clin Invest. 1978;61(6):1488–1497. https://doi.org/10.1172/JCI109069.
© 1978 The American Society for Clinical Investigation
Published June 1, 1978 - Version history
View PDF
Abstract

The effects of endogenous and exogenous hyperglucagonemia on the specific binding of glucagon to hepatocyte receptors was studied, as was the response of cAMP to glucagon. In streptozotocin diabetic rats, blood glucose and plasma glucagon increased and plasma insulin decreased as compared with controls. Insulin treatment in diabetic rats restored blood glucose and plasma glucagon toward normal and elevated plasma insulin. Specific binding of 125I-glucagon to isolated hepatocytes (106 cells) decreased in diabetic rats (8.17±0.38%) compared to controls (14.05±0.87%) and was restored by insulin treatment (12.25±0.93%). Specific binding of 125I-insulin in controls was 7.30±10.16%; it increased in diabetic rats to 12.50±0.86%, and decreased in diabetic rats after insulin treatment (9.08±0.87%). Scatchard analysis and the competition plots of the data indicate that decreased glucagon binding and increased insulin binding in diabetes were due to change in the number of receptors rather than a change in their affinity. Hepatocyte cAMP response to glucagon (0.25-5.0 ng/ml) was almost abolished in diabetic rats and was restored with insulin treatment.

Specific glucagon binding by hepatocytes from chronically hyperglucagonemic (glucagon injected) rats was decreased (P < 0.005) to 8.76±0.61% compared with controls (13.20±0.74%) and acutely hyperglucagonemic animals (13.53±1.33%). The decreased binding was associated with a 70% decrease in hepatocyte cAMP response to glucagon compared with a normal response in acutely hyperglucagonemic rats.

These data appear to support the concept of receptor regulation by ambient hormone level. In both endogenous and exogenous hyperglucagonemia, however, there was a disproportionately large decrease in cAMP response to glucagon compared to the decrease in glucagon binding.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1488
page 1488
icon of scanned page 1489
page 1489
icon of scanned page 1490
page 1490
icon of scanned page 1491
page 1491
icon of scanned page 1492
page 1492
icon of scanned page 1493
page 1493
icon of scanned page 1494
page 1494
icon of scanned page 1495
page 1495
icon of scanned page 1496
page 1496
icon of scanned page 1497
page 1497
Version history
  • Version 1 (June 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts